GO:0004335 galactokinase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004335 galactokinase activity is a molecular function defined as the catalysis of D-galactose + ATP = alpha-D-galactose 1-phosphate + ADP + 2 H+.
• The enzyme galactokinase (GALK1 in humans) performs the first committed step of the Leloir pathway, trapping galactose as galactose 1-phosphate.
• GALK1 deficiency causes galactosemia type II, a disorder that can present with cataracts and is included in many neonatal screening programs.
• Human galactokinase has a flexible active site that accepts promiscuous substrates, which is relevant for inhibitor and enzyme-engineering studies.
• Engineered variants of human galactokinase with improved activity and stability have been generated for therapeutic and biotechnological applications.
• Galactokinase activity is not limited to humans; it is also found in bacteria such as Streptococcus thermophilus and in fetal human organs.
Description
Galactokinase activity (GO:0004335) is a molecular function that catalyzes the ATP-dependent phosphorylation of D-galactose to alpha-D-galactose 1-phosphate. This reaction is the first committed step of the Leloir pathway, the main route for galactose metabolism in humans and many other organisms. Because the product galactose 1-phosphate is retained in the cell, galactokinase effectively traps dietary and endogenous galactose for further conversion into glucose 1-phosphate and UDP-galactose. The enzyme is therefore central to normal galactose utilization and to the pathophysiology of galactosemia when it is deficient. Researchers study galactokinase activity for several reasons. First, loss-of-function variants in the human GALK1 gene cause galactosemia type II, a condition that can lead to early-onset cataracts and is part of many newborn screening panels. Second, the enzyme is a target for inhibitor development, because blocking galactokinase could reduce toxic galactose 1-phosphate accumulation in classic galactosemia. Third, galactokinase is used in biotechnology for galactose detection and for engineered metabolic pathways, and its substrate promiscuity and stability have been optimized by protein engineering. Finally, galactokinase activity is measurable in diverse biological samples, from human fetal organs to bacterial cultures, making it a tractable model enzyme for enzymology and metabolic research. This article summarizes the authoritative GO definition, the catalytic mechanism, the genes and proteins involved, disease links, and the experimental methods used to study galactokinase activity. It is intended for researchers who need a concise, citation-backed overview that can support grant writing, experimental design, and AI-assisted literature retrieval.
galactokinase activity At A Glance
| GO ID | GO:0004335 |
|---|---|
| GO term | galactokinase activity |
| Ontology | molecular_function |
| Definition | Catalysis of the reaction: D-galactose + ATP = alpha-D-galactose 1-phosphate + ADP + 2 H+. |
| Synonym | ATP:D-galactose 1-phosphotransferase activity; ATP:D-galactose-1-phosphotransferase activity; galactokinase (phosphorylating) |
| Major function | First committed step of the Leloir pathway; phosphorylates D-galactose to alpha-D-galactose 1-phosphate. |
| Human gene | GALK1 (galactokinase 1) |
| Associated disease | Galactosemia type II (GALK1 deficiency), often with cataracts. |
| Pathway context | Leloir pathway of galactose metabolism. |
| Subcellular context | Cytosolic enzyme in human cells. |
| Research relevance | Target for inhibitor development, newborn screening, enzyme engineering, and metabolic engineering. |
What Is GO:0004335?
According to the Gene Ontology, GO:0004335 galactokinase activity is defined as the catalysis of the reaction: D-galactose + ATP = alpha-D-galactose 1-phosphate + ADP + 2 H+. In other words, the enzyme transfers the terminal phosphate group of ATP to the C1 hydroxyl of D-galactose, producing alpha-D-galactose 1-phosphate and ADP while releasing protons. This activity is a molecular_function, meaning it describes what the protein does at the biochemical level rather than where it acts or which pathway it belongs to. Synonyms include ATP:D-galactose 1-phosphotransferase activity, ATP:D-galactose-1-phosphotransferase activity, and galactokinase (phosphorylating). The reaction is the first step of the Leloir pathway and is required for galactose catabolism in humans and many microbes.
Why Is galactokinase activity Important in Cell Biology?
Galactokinase activity is important because it controls the entry of galactose into the Leloir pathway and thus determines how much galactose 1-phosphate is produced in cells. In humans, reduced GALK1 activity causes galactosemia type II, a disease that can present with cataracts and that is detected by newborn screening in many countries. In classic galactosemia, inhibition of galactokinase is being explored as a strategy to lower the accumulation of toxic galactose 1-phosphate. Beyond disease, galactokinase is a workhorse enzyme in biotechnology and enzymology, and its substrate promiscuity and stability have been engineered for practical applications. The enzyme is also found in bacteria and in human fetal tissues, making it a useful model for comparative and developmental studies.
• Catalyzes the first committed step of the Leloir pathway, converting D-galactose to alpha-D-galactose 1-phosphate.
• Deficiency of human GALK1 causes galactosemia type II, which can lead to cataracts and is included in neonatal screening programs.
• Galactokinase inhibitors are investigated as potential therapeutics to reduce galactose 1-phosphate accumulation in classic galactosemia.
• The enzyme is a target for protein engineering to improve activity and stability for therapeutic and biotechnological use.
• Human galactokinase shows substrate promiscuity, which is relevant for designing selective inhibitors and for understanding enzyme flexibility.
• Galactokinase activity is measurable in human fetal organs, providing insights into developmental galactose metabolism.
• The enzyme is present in bacteria such as Streptococcus thermophilus, where it contributes to galactose utilization.
• Galactokinase activity assays are used in clinical diagnostics and in newborn screening for galactosemia.
• The enzyme is a model system for studying kinase mechanism, substrate recognition, and allosteric regulation.
• Galactokinase is used in metabolic engineering and synthetic biology for galactose-dependent circuits and biosensors.
Molecular Mechanism of galactokinase activity
Substrate binding and specificity
In simple terms: The enzyme grabs galactose and ATP and holds them in the right position to react.
Galactokinase binds D-galactose and ATP in a sequential manner. The active site accommodates the galactose ring and the ATP phosphate groups, positioning the C1 hydroxyl of galactose near the gamma-phosphate of ATP. Human galactokinase exhibits substrate promiscuity, meaning it can phosphorylate some galactose analogs, which has implications for inhibitor design and for understanding enzyme flexibility. Structural and activity studies of human galactokinase inhibitors have revealed key interactions that determine substrate and inhibitor specificity.
Catalytic step and product formation
In simple terms: The enzyme transfers a phosphate from ATP onto galactose, making galactose 1-phosphate.
The catalytic step involves direct transfer of the gamma-phosphate of ATP to the C1 hydroxyl of D-galactose, yielding alpha-D-galactose 1-phosphate and ADP, with release of protons. This reaction is the first committed step of the Leloir pathway, and the product galactose 1-phosphate is retained in the cell for further metabolism. The reaction is essentially irreversible under physiological conditions, which helps drive galactose into the pathway.
Cofactors and metal requirements
In simple terms: The enzyme uses ATP as a phosphate donor and typically needs magnesium ions to work.
Galactokinase uses ATP as the phosphate donor and requires divalent metal ions, typically Mg2+, for catalysis. The metal ion coordinates the ATP phosphates and stabilizes the transition state during phosphoryl transfer. This dependence on magnesium is a common feature of kinases and is exploited in activity assays that include MgCl2.
Regulation and inhibition
In simple terms: The enzyme can be turned down by inhibitors or by changes in its own stability.
Human galactokinase activity can be inhibited by small molecules that compete with galactose or ATP binding, and such inhibitors are being developed as potential therapeutics for classic galactosemia. The enzyme's activity and stability can also be improved by protein engineering, indicating that its function is tunable. In bacteria such as Streptococcus thermophilus, galactokinase activity is part of a regulated galactose utilization system.
Tissue and developmental context
In simple terms: The enzyme is active in different tissues and changes during development.
Galactokinase activity has been measured in human fetal organs, showing tissue-specific and developmental patterns of expression. In clinical studies, galactokinase activity in patients with idiopathic presenile and senile cataract has been examined, linking enzyme activity to lens biology. These findings indicate that galactokinase activity is not uniform across tissues and can be relevant to age-related and developmental phenotypes.
Key Genes Involved in GO:0004335 galactokinase activity
The following genes and proteins are directly or indirectly involved in galactokinase activity and its biological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| GALK1 | Encodes human galactokinase, the enzyme that catalyzes the first step of the Leloir pathway. | Mutations cause galactosemia type II; target for inhibitor and enzyme engineering studies. |
| GALK2 | Encodes a second human galactokinase-like enzyme (N-acetylgalactosamine kinase). | Related enzyme with overlapping substrate specificity; useful for comparative studies. |
| GALT | Encodes galactose-1-phosphate uridylyltransferase, the second enzyme of the Leloir pathway. | Deficiency causes classic galactosemia; GALK1 inhibitors are explored to reduce substrate load. |
| GALE | Encodes UDP-galactose-4-epimerase, the third enzyme of the Leloir pathway. | Deficiency causes epimerase deficiency galactosemia; relevant to pathway flux. |
| AKR1B1 | Aldose reductase, converts galactose to galactitol in a competing pathway. | Contributes to cataract formation in galactosemia; relevant to GALK1 disease models. |
| SLC2A1 | GLUT1 glucose transporter, also transports galactose. | Affects galactose uptake and availability for galactokinase. |
| SLC5A1 | Sodium-glucose cotransporter 1, involved in galactose absorption. | Relevant to dietary galactose handling and galactosemia management. |
| G6PD | Glucose-6-phosphate dehydrogenase, linked to pentose phosphate pathway. | May influence galactose metabolism indirectly; studied in galactosemia models. |
| HSPA1A | Heat shock protein 70, assists protein folding. | May influence galactokinase stability and folding in cells. |
| HSP90AA1 | Heat shock protein 90, chaperone for kinases. | Potential regulator of galactokinase folding and stability. |
| ST3GAL1 | Sialyltransferase, uses galactose derivatives. | Downstream consumer of galactose metabolites; relevant to pathway flux. |
| B4GALT1 | Beta-1,4-galactosyltransferase, uses UDP-galactose. | Links galactose metabolism to glycoconjugate synthesis. |
| UGP2 | UDP-glucose pyrophosphorylase, supplies UDP-glucose for GALT reaction. | Supports Leloir pathway flux and galactose utilization. |
| PGM1 | Phosphoglucomutase 1, interconverts glucose 1-phosphate and glucose 6-phosphate. | Connects galactose metabolism to glycolysis. |
| GPI | Glucose-6-phosphate isomerase, glycolysis enzyme. | Downstream of galactose-derived glucose 6-phosphate. |
| HK1 | Hexokinase 1, phosphorylates glucose and galactose. | Can compete with galactokinase for galactose phosphorylation. |
| PFKM | Phosphofructokinase, muscle type, glycolysis regulator. | Affects metabolic flux from galactose. |
| LDHA | Lactate dehydrogenase A, converts pyruvate to lactate. | Reflects glycolytic flux from galactose in cell models. |
How Is galactokinase activity Regulated?
Galactokinase activity is regulated at multiple levels. At the transcriptional level, GALK1 expression can vary by tissue and developmental stage, as shown by measurements in human fetal organs. At the protein level, the enzyme's stability and activity can be modulated by chaperones and by engineered mutations that improve folding and catalytic efficiency. Pharmacological regulation is also possible: small-molecule inhibitors of human galactokinase have been developed and characterized, and these compounds can reduce enzyme activity in vitro. In bacteria such as Streptococcus thermophilus, galactokinase activity is part of a regulated galactose utilization system that responds to substrate availability. In humans, the pathway is also influenced by the availability of galactose from diet and by the activity of downstream Leloir enzymes such as GALT and GALE.
galactokinase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GALK1 | Galactosemia type II; cataracts | GALK1 knockout cell lines (e.g., HEK293, HepG2) and patient-derived fibroblasts. |
| GALT | Classic galactosemia; galactose 1-phosphate toxicity | GALT knockout cells treated with galactokinase inhibitors. |
| GALE | Epimerase deficiency galactosemia | GALE knockout cell models to study pathway flux. |
| AKR1B1 | Cataract formation via galactitol accumulation | AKR1B1 overexpression or knockout in lens epithelial cells. |
| GALK2 | Related kinase; N-acetylgalactosamine metabolism | GALK2 knockout or overexpression for substrate specificity studies. |
Galactosemia type II (GALK1 deficiency)
Biallelic loss-of-function variants in GALK1 cause galactosemia type II, a rare inborn error of galactose metabolism. Patients may present with cataracts, and the condition is included in many newborn screening programs that measure galactokinase activity or related metabolites. Unlike classic galactosemia, galactosemia type II is generally considered milder, but early diagnosis and dietary galactose restriction are important to prevent lens damage. Studies of galactokinase activity in patients with idiopathic presenile and senile cataract have also suggested a link between reduced enzyme activity and lens pathology.
Classic galactosemia and therapeutic inhibition of galactokinase
Classic galactosemia is caused by deficiency of GALT, the second enzyme of the Leloir pathway, leading to accumulation of galactose 1-phosphate, which is toxic. Because galactokinase produces galactose 1-phosphate, pharmacological inhibition of galactokinase is being explored as a strategy to reduce the toxic metabolite in classic galactosemia. Inhibitors of human galactokinase have been developed and characterized, and they represent potential pharmacological chaperones or direct inhibitors for therapeutic intervention.
Cataract and age-related lens pathology
Galactokinase activity has been measured in patients with idiopathic presenile and senile cataract, and altered activity has been reported in some cases. In galactosemia, galactose is converted to galactitol by aldose reductase, causing osmotic stress in the lens and contributing to cataract formation. Therefore, galactokinase activity is relevant not only to rare metabolic disease but also to more common lens pathologies.
Biotechnological and metabolic engineering applications
Galactokinase activity is exploited in biotechnology for galactose detection, metabolic engineering, and the construction of galactose-responsive genetic circuits. Engineered variants with improved activity and stability have been generated to enhance these applications. In bacteria such as Streptococcus thermophilus, galactokinase contributes to galactose utilization, which is relevant for dairy fermentation and microbial metabolism.
From galactokinase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GALK1 reduce galactokinase activity and cause galactose sensitivity? | GALK1 knockout cell lines (CRISPR KO). |
| Can a specific point mutation in GALK1 alter substrate specificity? | Point-mutation knock-in cell lines expressing mutant GALK1. |
| Does tagging GALK1 with a fluorescent protein affect its localization? | Knock-in of GFP or HA tag at the endogenous GALK1 locus. |
| Does overexpression of GALK1 increase galactose 1-phosphate levels? | GALK1 overexpression cell lines. |
| Can a candidate inhibitor reduce galactokinase activity in cells? | Wild-type cells treated with small-molecule inhibitors. |
| Does GALK1 deficiency affect lens cell osmolality? | Lens epithelial cell models with GALK1 KO or AKR1B1 overexpression. |
How to Study the galactokinase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Coupled enzymatic assay | Galactokinase activity via NADH or ADP production | Clinical diagnosis and newborn screening. |
| Mass spectrometry | Galactose 1-phosphate and related metabolites | Metabolic flux studies in cells and tissues. |
| X-ray crystallography | Three-dimensional structure of galactokinase | Structure-based inhibitor design. |
| Molecular dynamics | Protein flexibility and substrate promiscuity | Understanding substrate specificity. |
| CRISPR knockout | Loss-of-function phenotypes | Validating GALK1 function in cells. |
| CRISPR knock-in | Tagged or mutant GALK1 expression | Localization and stability studies. |
| RNA-seq | Transcriptional changes after GALK1 perturbation | Pathway analysis and off-target effects. |
| Western blot | Protein expression and stability | Evaluating engineered GALK1 variants. |
Enzymatic activity assays
Galactokinase activity is typically measured using coupled enzymatic assays that monitor the formation of galactose 1-phosphate or ADP. These assays can be performed on cell lysates, tissue homogenates, or purified enzyme preparations. They are used in clinical diagnostics for galactosemia and in newborn screening programs.
Structural and biophysical methods
X-ray crystallography, NMR, and molecular dynamics simulations have been used to study the active site of human galactokinase and its interactions with substrates and inhibitors. These methods reveal how substrate promiscuity arises and how inhibitors can be designed.
Cell-based metabolic assays
Cellular galactose consumption and galactose 1-phosphate accumulation can be measured by mass spectrometry or enzymatic assays in wild-type and GALK1-mutant cells. These approaches are used to evaluate the impact of GALK1 variants and inhibitors on pathway flux.
Genetic and CRISPR screens
CRISPR knockout and knock-in screens can identify genes that modify galactokinase activity or galactose sensitivity. Such screens are useful for discovering synthetic lethal interactions and for validating candidate therapeutic targets.
How CRISPR Can Be Used to Study GO:0004335 galactokinase activity
Knockout
CRISPR knockout of GALK1 is used to create isogenic cell lines that lack galactokinase activity, enabling studies of galactose sensitivity, galactose 1-phosphate accumulation, and cataract-related phenotypes. These models are also useful for testing whether candidate inhibitors require GALK1 for their effects.
Point Mutation
Point mutations identified in patients with galactosemia type II can be introduced into the endogenous GALK1 locus using CRISPR prime editing or homology-directed repair. Such models allow researchers to test the functional impact of specific variants on enzyme activity and stability.
Knock-in
Knock-in of fluorescent or affinity tags at the GALK1 locus enables live-cell imaging and proteomic analysis of the endogenous enzyme. Knock-in of reporter cassettes can also be used to monitor GALK1 promoter activity in different tissues.
Overexpression
Overexpression of wild-type or engineered GALK1 variants can be achieved by lentiviral transduction or safe-harbor knock-in. These models are used to study the consequences of increased galactokinase activity on metabolic flux and to produce enzyme for biotechnological applications.
How EDITGENE Supports galactokinase activity Research
Researchers studying galactokinase activity-related genes often need to determine whether a candidate gene is causally involved in galactose metabolism, disease phenotypes, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for galactokinase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| GALK1 Knockout HEK293 Cell Line | EDJ-KQ3079 | Human | 2584 | Details Get a Quote |
| GALK2 Knockout HEK293 Cell Line | EDJ-KQ4678 | Human | 2585 | Details Get a Quote |
| GALK1 Knockout HeLa Cell Line | EDJ-KQ22996 | Human | 2584 | Details Get a Quote |
| GALK1 Knockout A-549 Cell Line | EDJ-KQ24371 | Human | 2584 | Details Get a Quote |
| GALK1 Knockout HCT 116 Cell Line | EDJ-KQ24372 | Human | 2584 | Details Get a Quote |
| GALK2 Knockout A-549 Cell Line | EDJ-KQ27378 | Human | 2585 | Details Get a Quote |
| GALK2 Knockout HCT 116 Cell Line | EDJ-KQ27379 | Human | 2585 | Details Get a Quote |
| GALK2 Knockout HeLa Cell Line | EDJ-KQ27380 | Human | 2585 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
Frequently Asked Questions About galactokinase activity
What is galactokinase activity?
Galactokinase activity (GO:0004335) is the catalysis of the reaction D-galactose + ATP = alpha-D-galactose 1-phosphate + ADP + 2 H+, the first step of the Leloir pathway.
What genes are involved in galactokinase activity?
The main human gene is GALK1, which encodes galactokinase; GALK2 encodes a related enzyme, and GALT and GALE encode downstream Leloir pathway enzymes.
What is the function of GALK1?
GALK1 encodes galactokinase, which phosphorylates galactose to galactose 1-phosphate, the first committed step in galactose metabolism.
What diseases are associated with galactokinase activity?
Deficiency of GALK1 causes galactosemia type II, which can present with cataracts; altered galactokinase activity has also been studied in age-related cataract.
How is galactokinase activity measured?
It is typically measured using coupled enzymatic assays that detect ADP or galactose 1-phosphate formation, often in cell lysates or tissue homogenates.
Can galactokinase be inhibited therapeutically?
Yes, small-molecule inhibitors of human galactokinase have been developed and are being explored to reduce galactose 1-phosphate accumulation in classic galactosemia.
Is galactokinase activity found in bacteria?
Yes, galactokinase activity has been detected in Streptococcus thermophilus and other bacteria, where it contributes to galactose utilization.
What is the Leloir pathway?
The Leloir pathway is the main route for galactose metabolism, consisting of galactokinase (GALK1), galactose-1-phosphate uridylyltransferase (GALT), and UDP-galactose-4-epimerase (GALE).
How can CRISPR be used to study galactokinase activity?
CRISPR knockout, knock-in, and point mutation can create isogenic cell models to test the effects of GALK1 variants on enzyme activity and disease phenotypes.
What are the synonyms for galactokinase activity?
Synonyms include ATP:D-galactose 1-phosphotransferase activity, ATP:D-galactose-1-phosphotransferase activity, and galactokinase (phosphorylating).
Conclusion
Galactokinase activity (GO:0004335) is a well-defined molecular function that catalyzes the first step of the Leloir pathway and is essential for galactose metabolism. Its importance spans rare disease, cataract biology, pharmacology, and biotechnology, with GALK1 as the central human gene. Researchers can study galactokinase activity using enzymatic assays, structural biology, and CRISPR-based cell models, and EDITGENE provides end-to-end services to generate these models efficiently. By combining authoritative GO annotation with real PubMed literature, this article provides a citation-backed resource for scientists, clinicians, and AI systems seeking accurate information on galactokinase activity.
References
- 1. Badiu Tișa I et al.. 2022. The Importance of Neonatal Screening for Galactosemia.. Nutrients 15(1) PMID: 36615667
- 2. McAuley M et al.. 2016. Galactokinase promiscuity: a question of flexibility?. Biochem Soc Trans 44(1):116-22 PMID: 26862196
- 3. Liu L et al.. 2015. Structure activity relationships of human galactokinase inhibitors.. Bioorg Med Chem Lett 25(3):721-7 PMID: 25553891
- 4. McAuley M et al.. 2018. Improving the Activity and Stability of Human Galactokinase for Therapeutic and Biotechnological Applications.. Chembiochem 19(10):1088-1095 PMID: 29505688
- 5. Hutkins R et al.. 1985. Galactokinase activity in Streptococcus thermophilus.. Appl Environ Microbiol 50(4):777-80 PMID: 4083880
- 6. Banford S et al.. 2021. Galactosemia: Towards Pharmacological Chaperones.. J Pers Med 11(2) PMID: 33562227
- 7. Simonelli F et al.. 1992. Galactokinase activity in patients with idiopathic presenile and senile cataract.. Metab Pediatr Syst Ophthalmol (1985) 15(4):53-6 PMID: 1305705
- 8. Shin-Buehring YS et al.. 1977. The activity of galactose-1-phosphate uridyltransferase and galactokinase in human fetal organs.. Pediatr Res 11(10 Pt 1):1045-51 PMID: 198730
